Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant growth in short interest in February. As of February 27th, there was short interest totaling 4,865,346 shares, a growth of 3,557.9% from the February 12th total of 133,008 shares. Based on an average trading volume of 40,722,544 shares, the days-to-cover ratio is presently 0.1 days. Approximately 120.2% of the shares of the stock are short sold. Approximately 120.2% of the shares of the stock are short sold. Based on an average trading volume of 40,722,544 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Avalon GloboCare Price Performance

Shares of NASDAQ:ALBT traded down $0.03 during midday trading on Tuesday, reaching $0.84. The company’s stock had a trading volume of 458,818 shares, compared to its average volume of 8,680,880. The business’s fifty day simple moving average is $0.93 and its 200-day simple moving average is $1.60. Avalon GloboCare has a fifty-two week low of $0.42 and a fifty-two week high of $7.89. The company has a market capitalization of $3.59 million, a P/E ratio of -0.24 and a beta of -0.24.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.